Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion's Aspira Labs Wins Coverage from CareFirst BCBS for OVA1

NEW YORK (GenomeWeb) – Vermillion said today that CareFirst BlueCross BlueShield (BCBS) has agreed to cover its OVA1 ovarian cancer test.

CareFirst BCBS covers more than 3 million patients in Maryland, Washington DC, and Virginia.

"This is our fourth recent announcement of new managed care contracts as we continue to expand our reach in our key strategic market areas," Valerie Palmieri, Vermillion's president and CEO said in a statement. Most recently, the company signed an agreement in July with Michigan healthcare insurance company Priority Health Managed Benefits.

OVA1 is a proteomic test intended for use in patients with an adnexal mass to determine prior to surgery whether the mass is likely malignant or benign and help physicians decide if a patient should be passed on to a gynecologic oncologist for the procedure.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more